AB1226 SIGNIFICANCE OF RO52 ANTIBODIES IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: INSIGHTS FROM A RETROSPECTIVE COHORT STUDY

间质性肺病 医学 回顾性队列研究 疾病 队列 抗体 肺 病理 内科学 免疫学
作者
C. Calomarde-Gómez,R. Ugena-García,P. Billi,Karina Portillo,F. Salabert-Carreras,C. Rocamora-Gisbert,Noemí Pérez,Annika Nack,Susana Holgado Pérez,M. Aparicio-Espinar,A L Prior,L. Gifre-Sala,L. Mateo-Soria,A. Riveros Fruitos,J. Font,I. Casafont-Solé
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
标识
DOI:10.1136/annrheumdis-2024-eular.3817
摘要

Background:

Interstitial lung disease (ILD) in systemic sclerosis (SSc) represents a negative impact on their quality of life and in mortality[1]. Anti-Ro52 positivity in ILD-SSc patients has shown a decrease in FVC and an increase in mortality[2]. Factors leading to progressive form of ILD and Progressive Pulmonary Fibrosis (PPF) have been described [3]. However, the involvement of anti-Ro52 positivity in the development of PPF among SSc-ILD patients remains not elucidated.

Objectives:

Primary outcome: assesing the relationship between anti-Ro52 and the development of PPF in patients with SSc-ILD. Secondary outcomes: describing SSc and ILD-SSc clinical features in anti-Ro52 positive patients, assessing changes in respiratory function tests during the initial 5 years of disease progression.

Methods:

Retrospective cohorts. SSc-ILD patients attended at the Germans Trias i Pujol Hospital between 2008 and 2018 were included. Baseline was defined as the date of the diagnosis of ILD-SSc. Information of clinical SSc characteristics, clinical-demographic variables and risk factors ILD was collected.

Results:

Thirty patients with SSc-ILD were included (22 females and 8 males) with a mean age of 59.6 years (SD 14.6), 46,8% were smokers and 15.6% had epidemiological risk factors for ILD. Median duration of follow-up was 67.3 months (SD 22.3). Seven patients met ATS criteria for PPF (4 UIP, 2 NSIP, 1 indefined). Clinical SSc characteristics are shown in Table 1 and immunological features in Table 2. Six patients were anti-Ro52+. Four patients presented diffuse cutaneous SSc and 2 limited cutaneous SSc. Baseline mean FVC was 75.3% (SD 34.4) and baseline mean DLCO was 61% (SD 8), whereas in the control group was FVC 81.2% (SD 18.8) (p=0.467) and DLCO 55.3% (SD 8) (p=0.399) The radiological patterns found were 2 NSIP (33.3%), 4 UIP (66.6%). When compared to the control group no significant differences were found in the prevalence of NSIP (33.3% vs 41.7%) and UIP (66.7% vs 29.2%) (p=0.199). None of them presented respiratory insufficiency. None of them met ATS criteria for PPF at 5 year follow-up, whereas 7 patients met PPF criteria in the control group (p= 0.290). No differences were found in the relative FVC loss at 5-year follow up (Ro52 + 2.8% vs control group –2.6%, p=0.362).

Conclusion:

No conclusive evidence was found to support a significant relationship between anti-Ro52 positivity and FFP. While the absence of statistical significance may suggest a lack of a strong association, it is important to note the trends of a lower FVC at baseline and a higher prevalence of UIP in anti-Ro52 that warrant further exploration.

REFERENCES:

[1] Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, Matucci-Cerinic M, Allanore Y. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum. 2016 Aug;46(1):115-23. doi: 10.1016/j.semarthrit.2016.02.005. Epub 2016 Feb 26. PMID: 27132536. [2] Sánchez-Montalvá A, Fernández-Luque A, Simeón CP, Fonollosa-Plà V, Marín A, Guillén A, Vilardell M. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-177-82. Epub 2014 Nov 5. PMID: 25372801. [3] Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021 Feb;80(2):219-227. doi: 10.1136/annrheumdis-2020-217455. Epub 2020 Sep 28. PMID: 32988845; PMCID: PMC7815627. Table 1. Clinical SSc characteristics (GI, gastrointestinal). Table 2. Immunological features including frequencies for ANA patterns (Anti-Scl70,Autoantibodies against topoisomerase I; Anti-CENA,Anti-centromere protein A antibodies; Anti-CENB, Anti-centromere protein B antibodies; Anti-RNA pol III, Anti-RNA polymerase III antibodies)

Acknowledgements:

NIL.

Disclosure of Interests:

None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被942685630采纳,获得10
1秒前
胖胖橘发布了新的文献求助10
1秒前
星辰大海的应助被霁月采纳,获得10
1秒前
2秒前
zhangyuqi完成签到,获得积分10
2秒前
默listening发布了新的文献求助10
2秒前
有流量发布了新的文献求助30
3秒前
godman605完成签到 ,获得积分10
3秒前
4秒前
石瑶完成签到,获得积分10
4秒前
顾矜的应助被Xin5599采纳,获得10
5秒前
陈_Ccc完成签到 ,获得积分10
5秒前
66Ku完成签到,获得积分10
6秒前
哈哈哈完成签到 ,获得积分10
6秒前
6秒前
夏天完成签到,获得积分10
6秒前
7秒前
科研小白发布了新的文献求助10
7秒前
鲤鱼鑫磊发布了新的文献求助10
7秒前
godman605关注了科研通微信公众号
8秒前
美丽发布了新的文献求助20
8秒前
豚豚完成签到,获得积分10
9秒前
9秒前
hhh完成签到,获得积分10
10秒前
一颗荔枝完成签到,获得积分10
11秒前
Monica发布了新的文献求助10
12秒前
zejuLong完成签到 ,获得积分10
12秒前
英俊的铭的应助被JerryPanJ采纳,获得10
13秒前
13秒前
一尾胖头鱼完成签到,获得积分10
14秒前
今后的应助被白华苍松采纳,获得10
14秒前
14秒前
星辰大海的应助被沦落而采纳,获得10
15秒前
muzi完成签到,获得积分10
15秒前
16秒前
阿九完成签到,获得积分10
16秒前
Lucas的应助被第三方公司采纳,获得10
17秒前
17秒前
健忘曼彤完成签到,获得积分10
18秒前
大气的杨完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820